Cetuximab

Cetuximab is a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is used in the treatment of KRAS wild-type metastatic colorectal cancer and squamous cell carcinoma of the head and neck (SCCHN). It inhibits tumor cell proliferation by blocking EGFR signaling. Mediocon Inc supplies pharmaceutical-grade Cetuximab API for oncology drug manufacturers.

Key Features

• Anti-EGFR chimeric monoclonal antibody
• IP/BP/EP/USP compliant quality
• Colorectal cancer and SCCHN treatment
• IV infusion formulation

Applications

• KRAS WT metastatic colorectal cancer
• Squamous cell carcinoma of head & neck
• Combination with FOLFIRI/FOLFOX
• Biopharmaceutical manufacturing

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings